Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies.

What It Covers

Researchers studied Somatostatin in this review publication.

The purpose of the study was to assess, via the metaanalysis of acromegaly studies, the clinical impact of SSA on glucose metabolism.

The outcomes analyzed were fasting plasma glucose, fasting plasma insulin, hemoglobin A(1c), and plasma glucose concentrations during oral glucose tolerance test.

Why It Was Studied

Somatostatin analogs (SSA) may influence glucose metabolism, but the clinical relevance of this effect is uncertain because trials performed so far are limited in terms of number of patients and heterogeneity for length and type of follow-up.

Eligibility criteria were: 1) duration of SSA treatment of at least 3 wk; 2) available numerical data for at least one of the four biochemical outcomes investigated; 3) measurement of the outcomes before and after SSA treatment; and 4) no selection of acromegalic patients for their responsivity to SSA.

Who the Included Studies Covered

The age groups tagged for this paper are adults, both men and women.

What Was Measured

Eligibility criteria were: 1) duration of SSA treatment of at least 3 wk; 2) available numerical data for at least one of the four biochemical outcomes investigated; 3) measurement of the outcomes before and after SSA treatment; and 4) no selection of acromegalic patients for their responsivity to SSA.

Topics PubMed links to this paper include Acromegaly, Blood Glucose, Glucose, Glycated Hemoglobin, Homeostasis, Hormone Antagonists and Insulin.

What This Means in Plain Language

This is a review of Somatostatin.

The abstract goes on to report its results in about 1 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2009 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Somatostatin compound page, all human trials.